Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.

Itatani T, Shimizu S, Iwasa M, Ohkusa Y, Hayakawa K.

Vaccine. 2013 Jun 12;31(27):2891-7. doi: 10.1016/j.vaccine.2013.03.032. Epub 2013 Apr 6.

PMID:
23570987
2.

Pertussis in adolescents and adults: should we vaccinate?

Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA.

Pediatrics. 2005 Jun;115(6):1675-84.

PMID:
15930232
3.

Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.

McGarry LJ, Krishnarajah G, Hill G, Masseria C, Skornicki M, Pruttivarasin N, Arondekar B, Roiz J, Pelton SI, Weinstein MC.

PLoS One. 2014 Jan 9;9(1):e72723. doi: 10.1371/journal.pone.0072723. eCollection 2014.

4.

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.

Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofi degli Atti ML, Giammanco A; Stage III Working Group..

Pediatrics. 2001 Nov;108(5):E81.

PMID:
11694665
5.

Cost effectiveness of pertussis vaccination in adults.

Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, Schauer S, Lieu TA.

Am J Prev Med. 2007 Mar;32(3):186-193.

PMID:
17296470
6.

Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.

Ekwueme DU, Strebel PM, Hadler SC, Meltzer MI, Allen JW, Livengood JR.

Arch Pediatr Adolesc Med. 2000 Aug;154(8):797-803.

PMID:
10922276
7.

[Whooping cough in Spain. Current epidemiology, prevention and control strategies. Recommendations by the Pertussis Working Group].

Campins M, Moreno-Pérez D, Gil-de Miguel A, González-Romo F, Moraga-Llop FA, Arístegui-Fernández J, Goncé-Mellgren A, Bayas JM, Salleras-Sanmartí L.

Enferm Infecc Microbiol Clin. 2013 Apr;31(4):240-53. doi: 10.1016/j.eimc.2012.12.011. Epub 2013 Feb 12. Review. Spanish.

PMID:
23411362
8.

Economic considerations for pertussis booster vaccination in adolescents.

Hay JW, Ward JI.

Pediatr Infect Dis J. 2005 Jun;24(6 Suppl):S127-33. Review.

PMID:
15931140
9.

Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.

Iskedjian M, Walker JH, Hemels ME.

Vaccine. 2004 Oct 22;22(31-32):4215-27.

PMID:
15474711
10.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov..

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
11.
12.

Cost-effectiveness of adult pertussis vaccination in Germany.

Lee GM, Riffelmann M, Wirsing von Konig CH.

Vaccine. 2008 Jul 4;26(29-30):3673-9. doi: 10.1016/j.vaccine.2008.04.068. Epub 2008 May 19.

PMID:
18538901
13.

A critical literature review of health economic evaluations in pertussis booster vaccination.

Millier A, Aballea S, Annemans L, Toumi M, Quilici S.

Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):71-94. doi: 10.1586/erp.11.94. Review.

PMID:
22280198
14.

Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly.

McGarry LJ, Krishnarajah G, Hill G, Skornicki M, Pruttivarasin N, Masseria C, Arondekar B, Pelton SI, Weinstein MC.

PLoS One. 2013 Sep 3;8(9):e67260. doi: 10.1371/journal.pone.0067260. eCollection 2013.

15.

Safe and effective booster immunization using DTaP in teenagers.

Okada K, Komiya T, Yamamoto A, Takahashi M, Kamachi K, Nakano T, Nagai T, Okabe N, Kamiya H, Nakayama T.

Vaccine. 2010 Nov 10;28(48):7626-33. doi: 10.1016/j.vaccine.2010.09.050. Epub 2010 Sep 28.

PMID:
20883738
16.

Cost-effectiveness of pertussis booster vaccination in the Netherlands.

Rozenbaum MH, De Cao E, Postma MJ.

Vaccine. 2012 Nov 26;30(50):7327-31. doi: 10.1016/j.vaccine.2012.06.026. Epub 2012 Jun 27.

PMID:
22749838
17.

Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.

Tozzi AE, Anemona A, Stefanelli P, Salmaso S, Ciofi degli Atti ML, Mastrantonio P, Giammanco A; Progetto Pertosse Study Group..

Pediatrics. 2001 Feb;107(2):E25.

PMID:
11158499
18.

Acellular pertussis vaccine safety and efficacy in children, adolescents and adults.

Casey JR, Pichichero ME.

Drugs. 2005;65(10):1367-89. Review.

PMID:
15977969
19.

Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.

Scuffham PA, McIntyre PB.

Vaccine. 2004 Jul 29;22(21-22):2953-64.

PMID:
15246632
20.

An economic evaluation of universal pertussis vaccination in Italy.

Beutels P, Bonanni P, Tormans G, Canale F, Crovari PC.

Vaccine. 1999 May 14;17(19):2400-9. Erratum in: Vaccine 2000 Mar 17;18(18):1970.

PMID:
10392622

Supplemental Content

Support Center